175 related articles for article (PubMed ID: 38599892)
21. New directions for induction immunosuppression strategy in solid organ transplantation.
Hawksworth JS; Leeser D; Jindal RM; Falta E; Tadaki D; Elster EA
Am J Surg; 2009 Apr; 197(4):515-24. PubMed ID: 19249743
[TBL] [Abstract][Full Text] [Related]
22. Steroid-free immunosuppression in organ transplantation.
Luo G; Falta EM; Elster EA
Curr Diab Rep; 2005 Aug; 5(4):305-10. PubMed ID: 16033684
[TBL] [Abstract][Full Text] [Related]
23. Intestinal graft versus native liver cytokine expression in a rat model of intestinal transplantation with and without donor-specific cell augmentation.
Levay-Young B; Gruessner SE; Shearer JD; Cheol Kim S; Nahkleh RE; Gruessner RW
J Surg Res; 2003 Sep; 114(1):78-89. PubMed ID: 13678702
[TBL] [Abstract][Full Text] [Related]
24. Non-HLA Antibodies May Accelerate Immune Responses After Intestinal and Multivisceral Transplantation.
Gerlach UA; Lachmann N; Ranucci G; Sawitzki B; Schoenemann C; Pratschke J; Dragun D; Pascher A
Transplantation; 2017 Jan; 101(1):141-149. PubMed ID: 27495766
[TBL] [Abstract][Full Text] [Related]
25. Tailored immunosuppression after kidney transplantation - a single center real-life experience.
Good-Weber M; Roos M; Mueller TF; Rüsi B; Fehr T
BMC Nephrol; 2020 Nov; 21(1):501. PubMed ID: 33228545
[TBL] [Abstract][Full Text] [Related]
26. Organ Procurement and Transplantation Network/Scientific Registry of Transplant Recipients 2014 Data Report: Intestine.
Cai J; Wu G; Qing A; Everly M; Cheng E; Terasaki P
Clin Transpl; 2014; ():33-47. PubMed ID: 26281125
[TBL] [Abstract][Full Text] [Related]
27. The value of extracorporeal photopheresis as an immunosuppression-modifying approach in solid organ transplantation: a potential solution to an unmet medical need.
Augusto JF; Benden C; Diekmann F; Zuckermann A
Front Immunol; 2024; 15():1371554. PubMed ID: 38846942
[TBL] [Abstract][Full Text] [Related]
28. Clinical outcomes of intestinal transplant recipients receiving maintenance basiliximab, sublingual tacrolimus and prednisone: A case series.
Di Cocco P; Martinino A; Bencini G; Christensen R; Valdepenas B; Petrochenkov E; Akshelyan S; Almario-Alvarez J; Spaggiari M; Tzvetanov I; Benedetti E
Hum Immunol; 2024 May; 85(3):110787. PubMed ID: 38480040
[TBL] [Abstract][Full Text] [Related]
29. Daclizumab and alemtuzumab as induction agents in adult intestinal and multivisceral transplantation: A comparison of two different regimens on 29 recipients during the early post-operative period.
Lauro A; Amaduzzi A; Dazzi A; Ercolani G; Zanfi C; Golfieri L; Grazi GL; Vivarelli M; Cescon M; Varotti G; Del Gaudio M; Ravaioli M; Siniscalchi A; Faenza S; D'Errico A; Di Simone M; Pironi L; Pinna AD
Dig Liver Dis; 2007 Mar; 39(3):253-6. PubMed ID: 17275428
[TBL] [Abstract][Full Text] [Related]
30. Intestinal Transplantation: International Outcomes.
Ganoza AJ; Farmer DG; Marquez MA; Mazariegos GV
Clin Transpl; 2014; ():49-54. PubMed ID: 26281126
[TBL] [Abstract][Full Text] [Related]
31. Transplantation and immunosuppression: a review of novel transplant-related immunosuppressant drugs.
Parlakpinar H; Gunata M
Immunopharmacol Immunotoxicol; 2021 Dec; 43(6):651-665. PubMed ID: 34415233
[TBL] [Abstract][Full Text] [Related]
32. The Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant Recipients.
OʼLeary JG; Samaniego M; Barrio MC; Potena L; Zeevi A; Djamali A; Cozzi E
Transplantation; 2016 Jan; 100(1):39-53. PubMed ID: 26680372
[TBL] [Abstract][Full Text] [Related]
33. Immunosuppression: practice and trends.
Kaufman DB; Shapiro R; Lucey MR; Cherikh WS; T Bustami R; Dyke DB
Am J Transplant; 2004; 4 Suppl 9():38-53. PubMed ID: 15113354
[TBL] [Abstract][Full Text] [Related]
34. Pediatric intestinal transplantation.
Soltys KA; Bond G; Sindhi R; Rassmussen SK; Ganoza A; Khanna A; Mazariegos G
Semin Pediatr Surg; 2017 Aug; 26(4):241-249. PubMed ID: 28964480
[TBL] [Abstract][Full Text] [Related]
35. Mycophenolic acid versus azathioprine as primary immunosuppression for kidney transplant recipients.
Wagner M; Earley AK; Webster AC; Schmid CH; Balk EM; Uhlig K
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007746. PubMed ID: 26633102
[TBL] [Abstract][Full Text] [Related]
36. The role of alemtuzumab in facilitating maintenance immunosuppression minimization following solid organ transplantation.
Agarwal A; Shen LY; Kirk AD
Transpl Immunol; 2008 Nov; 20(1-2):6-11. PubMed ID: 18824230
[TBL] [Abstract][Full Text] [Related]
37. Complete freedom from rejection after intestinal transplantation using a new tolerogenic protocol combined with low immunosuppression.
Pirenne J; Koshiba T; Geboes K; Emonds MP; Ferdinande P; Hiele M; Nevens F; Waer M
Transplantation; 2002 Mar; 73(6):966-8. PubMed ID: 11923701
[TBL] [Abstract][Full Text] [Related]
38. Clinical aspects of sensitization.
Katznelson S; Bhaduri S; Cecka JM
Clin Transpl; 1997; ():285-96. PubMed ID: 9919412
[TBL] [Abstract][Full Text] [Related]
39. Alemtuzumab Induction Versus Conventional Immunosuppression in Heart Transplant Recipients.
Gale SE; Ravichandran B; Ton VK; Pham S; Reed BN
J Cardiovasc Pharmacol Ther; 2019 Sep; 24(5):435-441. PubMed ID: 31035777
[TBL] [Abstract][Full Text] [Related]
40. Intestine and multivisceral transplantation in the United States: a report of 20-year national registry data (1990-2009).
Cai J
Clin Transpl; 2009; ():83-101. PubMed ID: 20524278
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
